The Market Mafia

[NYPharmer1]

GNLK - The Future Of Medicine Is Here: Personalization Via DNA
Our new company profile will feature an up and coming high growth company thath as been making waves accross the investment community the last two years.

The company was Ranked Number 92 Fastest Growing Company in North Amerca on Deloitte's 2009 Technology Fast 500TM.


GeneLink experienced 1,991 percent growth during this period., 2004-2009.

"Being named to the Deloitte 500 is an outstanding achievement", said Monte Taylor, GeneLink CEO. "Substantially all of GeneLink`s revenue commenced with the launch of GeneWize Life Sciences, Inc. in the third quarter of 2008 and was based on roughly a half a year of revenue producing operations. Revenue for 2009 has already exceeded fiscal year 2008 and, assuming current trends at GeneWize continue, 2010 revenue should be even greater. As we continue to expand our science, product offerings, and the scope of our marketing efforts, we look forward to future growth."

Products Target Market: 1+ Trillion Dollars
Patents: 20+ Including On The DNA Collection System
Stage: High Growth, Young Company
Company Profile Date: Monday, February, 15, 2010


Today's company we are bringing to your attention is much more than the simplicity behind it being another stock market play. It is food for thought, a closer look at the future, and an investment in what could be the "Next Monster Company" as dubbed by the company's management and several other industry experts.

Following the Human Genome Project (HGP) and the successful mapping of the human DNA which was completed in 2003. Many new capabilities once thought out of our reach have become feasible, making the impossible, possible.

HGP's Impact On Medicine

All diseases have a genetic component, whether inherited or resulting from the body's response to environmental stresses like viruses or toxins. The successes of the HGP have even enabled researchers to pinpoint errors in genes--the smallest units of heredity--that cause or contribute to disease.


The ultimate goal is to use this information to develop new ways to treat, cure, or even prevent the thousands of diseases that afflict humankind. But the road from gene identification to effective treatments is long and fraught with challenges. In the meantime, biotechnology companies are racing ahead with commercialization by designing diagnostic tests to detect errant genes in people suspected of having particular diseases or of being at risk for developing them.Source: http://www.ornl.gov/sci/techresources/Human_Genome/medicine/medicine.shtml

Long before it was trendy for companies to begin talking about "personalized medicine", GeneLink (OTC: GNLK) was taking a leadership roll in the development of individualized therapies by focusing on four important genomic research areas:
Nutragenetics - The study of the relationship between our nutrient intake and gene function, with a particular emphasis of how this information could be applied to optimize an individual’s overall health regimen.
Dermagenetics - GeneLink’s pioneering research and development efforts literally launched the exciting new field of Dermagenetics® –the scientific application of genomic sciences to guide personalized, more effective skin care products and therapies.
Applied Technologies - GeneLink innovations led the company to develop a proprietary mass customization system for nutritional supplements and skin care product delivery. In 2005, GeneLink introduced DNA UltraCustom™ - the first scientifically proven anti-aging skin-care products for consumers based on their individual Skin-DNA profile.
Pharmacogenenomics – The study of the effects of individual genetic variations on drug response aimed at the development of therapies that maximize benefit or minimize side effects in individuals.
To support its vision, GeneLink has developed an impressive portfolio of DNA-based assessments and proprietary systems for individually tailored product manufacture and delivery. Each (patented or patent pending) GeneLink "panel" design is based on a carefully selected set of SNPs associated with a particular physiologic condition or imbalance such as cardiovascular health, oxidative stress, bone metabolism, etc. To enable this, Genelink has created the only patented, FDA reviewed, non-invasive, self-administered DNA collection system available today (US patent 6,291,171). The process starts when a person simply swabs the inside of their mouth (inner cheek) and mails the swabs back to GeneLink's laboratories. The DNA is analyzed for a SNP profile to determine:
VIDEO COVERAGE:

Story developing...